Last line of defence crumbling: WHO report on global antimicrobial resistance

Drug resistance to carbapenem antibiotics, which are used as a last-resort for treating hospital acquired bacterial infections caused by Klebsiella pneumoniae, such as pneumonia, bloodstream infections and infections in newborns, has spread to all regions of the world. This is the key finding by the World Health Organization (WHO) in its first ever report on antimicrobial resistance globally.

Drug resistance to carbapenem antibiotics, which are used as a last-resort for treating hospital acquired bacterial infections caused by Klebsiella pneumoniae, such as pneumonia, bloodstream infections and infections in newborns, has spread to all regions of the world. This is the key finding by the World Health Organization (WHO) in its first ever report on antimicrobial resistance globally.

The WHO also found that in some countries, because of the growing problem of drug resistance, carbapenem antibiotics would not...

Welcome to Scrip

Create an account to read this article

More from Anti-infective

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.